|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 166.8 USD | -0.57% |
|
+1.33% | +7.67% |
| 05:07pm | AbbVie Says Rinvoq Shows Superiority Versus Dupixent in Atopic Dermatitis Trial Primary Endpoint | MT |
| 12:11pm | Scholz promises support for pharma sector in Germany as Merck invests | RE |
AbbVie said upadacitinib achieved clinical remission and endoscopic response at one year in a Phase 3 maintenance study in patients with Crohn's disease. "AbbVie: Upadacitinib Achieved Clinical Remission at One Year in Crohn's Disease" at 9:23 a.m. ET incorrectly called the drug epadacitinib.
(END) Dow Jones Newswires
05-11-22 1052ET
| 1st Jan change | Capi. | |
|---|---|---|
| +7.67% | 297B | |
| +24.17% | 562B | |
| -6.39% | 358B | |
| +19.35% | 322B | |
| +13.45% | 219B | |
| +6.04% | 199B | |
| -10.51% | 196B | |
| -11.31% | 149B | |
| -6.87% | 146B | |
| +2.07% | 117B |
ABBVIE INC. 
